메뉴 건너뛰기




Volumn 22, Issue 6, 2003, Pages 871-874

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction;Artigo recomendados do mês

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 3A4; ERYTHROMYCIN; PRAVASTATIN; RIFAMPICIN; TROLEANDOMYCIN;

EID: 0042318538     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (1)

References (26)
  • 1
    • 0003306666 scopus 로고    scopus 로고
    • The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin
    • Abstract 2086
    • Lau WC, Waskell LA, Neer CJ, Carville DGM, Bates ER. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 2000;102 (supl): II-429. Abstract 2086
    • (2000) Circulation , vol.102 , Issue.SUPPL.
    • Lau, W.C.1    Waskell, L.A.2    Neer, C.J.3    Carville, D.G.M.4    Bates, E.R.5
  • 2
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction
    • Lau WC, Waskell LA, Watkins PB, Neer CJ, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003;107:32-7.
    • (2003) Circulation , vol.107 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3    Neer, C.J.4
  • 3
    • 0035124920 scopus 로고    scopus 로고
    • Platelet-active drugs. The relationship among dose, effectiveness, and side effects
    • Patrono C, Coller B, Dalen JE, FitzGerald GA, et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
    • (2001) Chest , vol.119
    • Patrono, C.1    Coller, B.2    Dalen, J.E.3    FitzGerald, G.A.4
  • 6
    • 0038508970 scopus 로고    scopus 로고
    • The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
    • Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Disp 2003;31:53-9.
    • (2003) Drug Metab Disp , vol.31 , pp. 53-59
    • Clarke, T.A.1    Waskell, L.A.2
  • 7
    • 0028083293 scopus 로고
    • The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A
    • Savi P, Combalbert J, Gaich C, Rouchon MC, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7.
    • (1994) Thromb Haemost , vol.72 , pp. 313-317
    • Savi, P.1    Combalbert, J.2    Gaich, C.3    Rouchon, M.C.4
  • 10
    • 0041434851 scopus 로고    scopus 로고
    • Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing
    • abstract 1009-117
    • Lau WC, Neer CJ, Watkins PB, Carville DG, et al. Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. JACC 2003;41 (6; suppl A): 225A (abstract 1009-117).
    • (2003) JACC , vol.41 , Issue.6 SUPPL. A
    • Lau, W.C.1    Neer, C.J.2    Watkins, P.B.3    Carville, D.G.4
  • 11
    • 0037382774 scopus 로고    scopus 로고
    • Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested
    • Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested (editorial). Circulation 2003;107:1568-9.
    • (2003) Circulation , vol.107 , pp. 1568-1569
    • Serebruany, V.L.1    Steinhubl, S.R.2    Hennekens, C.H.3
  • 14
    • 0041936209 scopus 로고    scopus 로고
    • Platelet aggregation
    • Michelson AD, ed. Amsterdam: Academic Press
    • Refaai MA, Laposata M. Platelet aggregation. In: Michelson AD, ed. Platelets. Amsterdam: Academic Press 2002;291-6.
    • (2002) Platelets , pp. 291-296
    • Refaai, M.A.1    Laposata, M.2
  • 16
    • 0017902733 scopus 로고
    • Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors
    • Born GV, Dearnley R, Foulks JG, Sharp DE. Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J Physiol 1978;280:193-212.
    • (1978) J Physiol , vol.280 , pp. 193-212
    • Born, G.V.1    Dearnley, R.2    Foulks, J.G.3    Sharp, D.E.4
  • 17
    • 0033007420 scopus 로고    scopus 로고
    • Inibidores da redutase do HMG-CoA: Breve revisao das suas propriedades farmacológicas e eficácia clínica na doença cardiovascular
    • Marques da Silva P. Inibidores da redutase do HMG-CoA: breve revisao das suas propriedades farmacológicas e eficácia clínica na doença cardiovascular. Rev Port Cardiol 1999;18:65-76.
    • (1999) Rev Port Cardiol , vol.18 , pp. 65-76
    • Marques da Silva, P.1
  • 18
    • 0042937903 scopus 로고    scopus 로고
    • Estatinas: Acçoes farmacológicas e características farmacocinéticas
    • Marques da Silva P. Estatinas: acçoes farmacológicas e características farmacocinéticas. Rev FML 1999;4 (supl. 5): 33-44.
    • (1999) Rev FML , vol.4 , Issue.SUPPL. 5 , pp. 33-44
    • Marques da Silva, P.1
  • 21
    • 0037326063 scopus 로고    scopus 로고
    • Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction of New Thrombus Occurrence (PRONTO) trial
    • Gubel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239-47.
    • (2003) Am Heart J , vol.145 , pp. 239-247
    • Gubel, P.A.1    Cummings, C.C.2    Bell, C.R.3    Alford, A.B.4    Meister, A.F.5    Serebruany, V.L.6
  • 22
    • 0041936203 scopus 로고    scopus 로고
    • Six-month mortality ratyes are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: An analysis from the Global Registry of Acute Coronary Events
    • abstract 822-3
    • Lim MJ, Spencer FA, Gore JM, Dabbous OH et al. Six-month mortality ratyes are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: an analysis from the Global Registry of Acute Coronary Events. JACC 2003;41 (6 supl A): 361A (abstract 822-3).
    • (2003) JACC , vol.41 , Issue.6 SUPPL. A
    • Lim, M.J.1    Spencer, F.A.2    Gore, J.M.3    Dabbous, O.H.4
  • 23
    • 0000210136 scopus 로고    scopus 로고
    • Complementary additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis
    • abstract 906-5
    • Bhatt DL, Foody JM, Hirsch AT, Ringleb P, Hacks W, Topol EJ. Complementary additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. JACC 2000;35 (2 supl A):326A (abstract 906-5).
    • (2000) JACC , vol.35 , Issue.2 SUPPL. A
    • Bhatt, D.L.1    Foody, J.M.2    Hirsch, A.T.3    Ringleb, P.4    Hacks, W.5    Topol, E.J.6
  • 24
    • 0037465436 scopus 로고    scopus 로고
    • Early and late effects of clopidogrel in patients with acute coronary syndromes
    • Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72.
    • (2003) Circulation , vol.107 , pp. 966-972
    • Yusuf, S.1    Mehta, S.R.2    Zhao, F.3    Gersh, B.J.4    Commerford, P.J.5
  • 25
    • 0036283175 scopus 로고    scopus 로고
    • Interaction between aspirin and ACE inhibitors: Resolving discrepancies using a meta-analysis
    • Takkouche B, Etminan M, Caamano F, Rochon PA. Interaction between aspirin and ACE inhibitors: resolving discrepancies using a meta-analysis. Drug Saf 2002;25:373-8.
    • (2002) Drug Saf , vol.25 , pp. 373-378
    • Takkouche, B.1    Etminan, M.2    Caamano, F.3    Rochon, P.A.4
  • 26
    • 0041434845 scopus 로고    scopus 로고
    • Atorvastatin does not affect the antiplatelet properties os clopidogrel in patients undergoing coronary stenting in randomized data from the Interaction of Atorvastatin and Clopidogrel (INTERACTION) trial. Poster presented. March 30 - April 2, Chicago, Illinois, USA
    • Serebruany V, Midei M, Malinin, Oshrine BR, Lowry DR, et al. Atorvastatin does not affect the antiplatelet properties os clopidogrel in patients undergoing coronary stenting in randomized data from the Interaction of Atorvastatin and Clopidogrel (INTERACTION) trial. Poster presented at ACC' 03 - 52nd Annual Scientific Session. March 30 - April 2, 2003, Chicago, Illinois, USA.
    • (2003) ACC' 03 - 52nd Annual Scientific Session
    • Serebruany, V.1    Midei, M.2    Malinin3    Oshrine, B.R.4    Lowry, D.R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.